HR 2090 · 109th Congress 2005–2007, ended

Food and Drug Administration Improvement Act of 2005

Latest action · Jun 21, 2006 Sponsor introductory remarks on measure. (CR H4358-4359)

Progress

Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.

  1. IntroducedMay 4, 2005
  2. Passed HouseNot reached
  3. Passed SenateNot reached
  4. To the PresidentNot reached
  5. Became lawNot reached

Summary

Food and Drug Administration Improvement Act of 2005 - Amends the Federal Food, Drug, and Cosmetic Act (FFDCA) to require that all fees collected for the review of applications for human drugs, devices, and animal drugs be deposited in the general fund of the Treasury. Makes available amounts necessary for the Secretary of Health and Human Services to review such applications.

Prohibits the Secretary from entering into agreements with persons from whom such fees are collected and terminates any existing agreements.

Requires the Secretary to: (1) establish the Center for Postmarket Drug Safety and Effectiveness within the Food and Drug Administration (FDA) to regulate approved drugs; and (2) transfer to the Center all responsibilities for such regulation from the Center for Drug Evaluation and Research and the Center for Biologics Evaluation and Research.

Allows the Secretary to require manufacturers of approved drugs to conduct studies of an identified significant safety issue with the drug.

Deems a drug to be misbranded if it does not meet the Secretary's requirements, including requirements for labeling and conducting postmarket studies.

Requires the Secretary to follow the interpretation that the FDA used in 1999 that the FFDCA and Public Health Service Act establish minimal standards but do not preclude additional state requirements. Requires the Secretary to cease intervening in product liability civil actions to argue another interpretation.

Sets forth procedures for advisory committee meetings to ensure that the committee is fairly balanced. Prohibits any exemptions from being granted to advisory committee members from rules prohibiting members from having a personal financial interest in the outcome.

Requires doctors to inform patients and obtain consent to prescribe an approved drug for a purpose that has not been approved by the FDA.

Cosponsors 15

Members who signed on, in the order they did. Signatures ran from May 4, 2005 to Jul 20, 2006; 2 are original cosponsors, there from the day it was introduced.

SeatCosponsorSigned on
D-MIBart StupakOriginalMay 4, 2005
D-CTRosa L. DeLauroOriginalMay 4, 2005
D-CALynn C. WoolseyJun 14, 2005
D-AZRaúl M. GrijalvaJun 14, 2005
D-HIEd CaseJul 25, 2005
D-ILLane EvansNov 18, 2005
D-MAStephen F. LynchNov 18, 2005
I-VTBernard SandersDec 7, 2005
D-PAChaka FattahDec 7, 2005
D-NYMichael R. McNultyDec 7, 2005
D-OHDennis J. KucinichDec 16, 2005
D-MIJohn Conyers, Jr.Dec 16, 2005
D-FLRobert WexlerDec 16, 2005
D-MAJames P. McGovernJul 20, 2006
D-ILJesse L. Jackson, Jr.Jul 20, 2006

Committees 1

Where it was sent and what each committee and subcommittee did with it, in order.

ChamberCommitteeWhat it did
HouseEnergy and Commerce Committee
Referred May 4, 2005
Health Subcommittee
Referred May 23, 2005

Actions 4

Everything that happened, newest first.

  1. Jun 21, 2006Sponsor introductory remarks on measure. (CR H4358-4359)
  2. May 23, 2005Referred to the Subcommittee on Health.
  3. May 4, 2005Introduced in House
  4. May 4, 2005Referred to the House Committee on Energy and Commerce.

Research

What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.

Printed hearings 1

Hearings whose printed record names this bill, newest first: hearings on it, and wider hearings where it came up.

NumberHearingCommitteeHeld
S. Hrg. 109-850BUILDING A 21ST CENTURY FDA: PROPOSALS TO IMPROVE DRUG SAFETY AND INNOVATION102 pagesHealth, Education, Labor, and Pensions CommitteeNov 16, 2006

Titles 2

Every title it has carried, official and short, at each stage.

Official Title as Introduced
To amend the Federal Food, Drug, and Cosmetic Act to provide for the deposit in the general fund of the Treasury of fees that are collected from manufacturers of drugs and devices under chapter VII of such Act, to terminate the authority of the Food and Drug Administration to negotiate with the manufacturers on particular uses of the fees, to establish a Center for Postmarket Drug Safety and Effectiveness, to establish additional authorities to ensure the safe and effective use of drugs, and for other purposes.
Short Titles as Introduced
Food and Drug Administration Improvement Act of 2005

Subjects

Assigned by the Library of Congress. Policy area: Health.

Text 1

Each version as it was printed, newest first.

  1. May 4, 2005Introduced in House

Support LegiList

This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.

Processed by Stripe in a separate window. LegiList never sees card details.

Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.